Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis.

CONCLUSIONS: Six months of infliximab treatment in patients with sarcoidosis led to signs of decreased CD4+ T-cell alveolitis and decreased mastocytosis in the lungs of responders.
PMID: 32275772 [PubMed - as supplied by publisher]

Source: Clinical and Developmental Immunology - April 9, 2020 Category: Allergy & Immunology Authors: Kullberg S, Rivera NV, Abo Al Hayja M, Grunewald J, Eklund A Tags: Clin Exp Immunol Source Type: research